Biogen

Biogen, a US-based Pharmaceutical Preparation Manufacturing company, reported total carbon emissions of approximately 356.2 million kg CO2e in 2025. This figure comprises 56.9 million kg CO2e from Scope 1 emissions, 1.5 million kg CO2e from Scope 2 (market-based) emissions, and 297.8 million kg CO2e from Scope 3 emissions. In 2024, total emissions were about 324.2 million kg CO2e, with Scope 1 at 56.6 million kg CO2e, Scope 2 (market-based) at 0.5 million kg CO2e, and Scope 3 at 267.1 million kg CO2e. This shows an increase in total emissions from 2024 to 2025.

Biogen has set ambitious climate commitments validated by the Science Based Targets initiative (SBTi). The company aims to achieve net-zero GHG emissions across its value chain by 2045. As part of its near-term targets, Biogen commits to reducing absolute Scope 1 and 2 GHG emissions by 55% by 2032, from a 2019 base year. For long-term goals, Biogen targets a 100% reduction in absolute Scope 1 and 2 GHG emissions by 2040 from a 2019 base year. Additionally, the company commits to reducing absolute Scope 3 GHG emissions by 90% by 2045, also from a 2019 base year. Biogen also aims for 80% of its suppliers by spend, covering purchased goods and services and capital goods, to have science-based targets by 2025.

The company has also set direct operational targets, aiming to reduce its Scope 1 emissions by 50% by 2030 from a 2019 baseline and achieve net-zero market-based Scope 2 emissions by 2030.